Luprolex Drug Interactions

No pharmacokinetic-based drug-drug interaction studies have been conducted with Leuprorelin (Luprolex). However, because leuprorelin acetate is a peptide that is primarily degraded by peptidase and not by cytochrome P-450 enzymes as noted in specific studies, and the drug is only about 46% bound to plasma proteins, drug interactions would not be expected to occur.
In males, since androgen deprivation treatment may prolong the QT interval, the concomitant use of Leuprorelin (Luprolex) with medicinal products known to prolong the QT interval or medicinal products able to induce Torsade de pointes such as Class IA (e.g. quinidine, disopyramide) or Class III (e.g. amiodarone, sotalol, dofetilide, ibutilide) antiarrhythmic medicinal products, methadone, moxifloxacin, antipsychotics, should be carefully evaluated.
Drug/Laboratory Test Interactions: Administration of Leuprorelin (Luprolex) in therapeutic doses results in suppression of the pituitary-gonadal system. Normal function is usually restored within three months after treatment is discontinued. Therefore, diagnostic tests of pituitary gonadotropic and gonadal functions conducted during treatment and for up to three months after discontinuation of Leuprorelin (Luprolex) may be misleading.